{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:09:36Z","timestamp":1789675776705,"version":"4.0.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018854","name":"Sirtex Medical Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jvir.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T15:41:10Z","timestamp":1718466070000},"page":"1253-1267.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the\u00a0Treatment of Liver Malignancy"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-2262","authenticated-orcid":false,"given":"Andrew S.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Jeyarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5891-3609","authenticated-orcid":false,"given":"David","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4177-6417","authenticated-orcid":false,"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navesh K.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-0752","authenticated-orcid":false,"given":"Daniel Y.","family":"Sze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S.","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2024.06.006_bib1","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4002","article-title":"Phase III multi-centre open-label randomized controlled trial of selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma: the SIRveNIB study","volume":"35","author":"Chow","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib3","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jvir.2024.06.006_bib4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1148\/radiol.2020191606","article-title":"Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study","volume":"296","author":"Hermann","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2024.06.006_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jvir.2024.06.006_bib6","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","article-title":"SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer","volume":"34","author":"van Hazel","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib7","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib8","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.21.01839","article-title":"Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial","volume":"39","author":"Mulcahy","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib9","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2010.28.5643","article-title":"Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy","volume":"28","author":"Hendlisz","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.bjc.6605770","article-title":"Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases","volume":"103","author":"Cosimelli","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jvir.2024.06.006_bib11","first-page":"679","article-title":"90Y radioembolization in the treatment of neuroendocrine neoplasms: results of an international multicenter retrospective study","volume":"63","author":"Schaarschmidt","year":"2022","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jvir.2024.06.006_bib12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00270-019-02350-2","article-title":"Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy","volume":"43","author":"Braat","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2024.06.006_bib13","article-title":"Selective internal radiation therapy of metastatic breast cancer to the liver: a meta-analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/liv.13382","article-title":"Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: a meta-regression study","volume":"37","author":"Cucchetti","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jvir.2024.06.006_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.21037\/jgo.2020.01.09","article-title":"Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm","volume":"11","author":"Jeyarajah","year":"2020","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib16","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1245\/s10434-017-5950-z","article-title":"The Post-SIR-Spheres Surgery Study (P4S): retrospective analysis of safety following hepatic resection or transplantation in patients previously treated with selective internal radiation therapy with yttrium-90 resin microspheres","volume":"24","author":"Pardo","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib17","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3390\/cancers11081155","article-title":"Hepatic resection following selective internal radiation therapy for colorectal cancer metastases in the FOXFIRE clinical trial: clinical outcomes and distribution of microspheres","volume":"11","author":"Winter","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvir.2024.06.006_bib18","article-title":"Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study","volume":"10","author":"de la Torre-Alaez","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jvir.2024.06.006_bib19","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.21037\/jgo.2017.09.10","article-title":"Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus","volume":"8","author":"Kennedy","year":"2017","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/hep.29207","article-title":"Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review","volume":"66","author":"Sangro","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2024.06.006_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jvir.2024.06.006_bib23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/bjc.2014.344","article-title":"Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer","volume":"111","author":"Cohen","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jvir.2024.06.006_bib24","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2013.12.040","article-title":"Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization","volume":"88","author":"Hickey","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jvir.2024.06.006_bib25","doi-asserted-by":"crossref","DOI":"10.2196\/11545","article-title":"TheraSphere yttrium-90 glass microspheres combined with chemotherapy versus chemotherapy alone in second-line treatment of patients with metastatic colorectal carcinoma of the liver: protocol for the EPOCH phase 3 randomized clinical trial","volume":"8","author":"Chauhan","year":"2019","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.jvir.2024.06.006_bib26","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1186\/s12885-022-10401-0","article-title":"Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases","volume":"22","author":"Fidelman","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jvir.2024.06.006_bib27","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jvir.2024.06.006_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","article-title":"Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma","volume":"31","author":"Zhan","year":"2020","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2024.06.006_bib29","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jhep.2021.07.037","article-title":"Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma","volume":"75","author":"Ricke","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jvir.2024.06.006_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib31","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jvir.2024.06.006_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/hpb.12326","article-title":"Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference","volume":"17","author":"Kennedy","year":"2015","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jvir.2024.06.006_bib33","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.31192","article-title":"Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases","volume":"124","author":"Kim","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2024.06.006_bib34","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.jvir.2022.03.327","article-title":"Abstract No. 246 CapTemY90 for grade 2 liver-dominant NET metastases","volume":"33","author":"Soulen","year":"2022","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2024.06.006_bib35","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/MPA.0000000000001115","article-title":"Safety and feasibility of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 2 liver-dominant metastatic neuroendocrine tumors","volume":"47","author":"Soulen","year":"2018","journal-title":"Pancreas"},{"key":"10.1016\/j.jvir.2024.06.006_bib36","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1007\/s00270-021-02906-1","article-title":"Intra-arterial therapies for liver metastatic breast cancer: a systematic review and meta-analysis","volume":"44","author":"Aarts","year":"2021","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.jvir.2024.06.006_bib37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib38","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jvir.2022.12.017","article-title":"Yttrium-90 radioembolization and concomitant systemic gemcitabine, cisplatin, and capecitabine as the first-line therapy for locally advanced intrahepatic cholangiocarcinoma","volume":"34","author":"Ahmed","year":"2023","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2024.06.006_bib39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000525489","article-title":"Selective internal radiation therapy with yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma: a phase 2 single-arm multicenter clinical trial","volume":"11","author":"Chan","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jvir.2024.06.006_bib40","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00259-018-3990-7","article-title":"A\u00a0MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy","volume":"45","author":"Manceau","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jvir.2024.06.006_bib41","first-page":"11","article-title":"A\u00a0pilot study of hepatic irradiation with yttrium-90 microspheres followed by immunotherapy with ipilimumab and nivolumab for metastatic uveal melanoma","volume":"37","author":"Minor","year":"2022","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.jvir.2024.06.006_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e16272","article-title":"The role of selective internal radiation therapy for liver metastases from pancreatic adenocarcinoma after progression on prior chemotherapy","volume":"39","author":"Hackett","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1245\/s10434-022-12708-5","article-title":"Selective internal radiation therapy (yttrium-90 glass microspheres) combined with capecitabine in the neoadjuvant setting of operable intrahepatic CHOlangiocarcinoma: the SIROCHO trial design","volume":"30","author":"Edeline","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib44","article-title":"A\u00a0pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases","volume":"2","author":"Arulananda","year":"2019","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.jvir.2024.06.006_bib45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/COC.0b013e3182546c50","article-title":"Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in\u00a0vivo double-arm-controlled phase II trial","volume":"36","author":"Gulec","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy151.274","article-title":"Selective internal radiation therapy (SIRT) with yttrium-90 microspheres and peri-procedural FOLFIRI\/irinotecan in pre-treated colorectal liver metastases patients: an analysis of outcomes from a UK Cancer Centre between 2009 and 2017","volume":"29","author":"Wilson","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib47","doi-asserted-by":"crossref","first-page":"944","DOI":"10.21037\/jgo.2019.05.10","article-title":"Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin","volume":"10","author":"Nezami","year":"2019","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2478\/raon-2020-0002","article-title":"Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study","volume":"54","author":"Aarts","year":"2020","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib49","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3390\/cancers14051162","article-title":"Safety and efficacy of ipilimumab plus nivolumab and sequential selective internal radiation therapy in hepatic and extrahepatic metastatic uveal melanoma","volume":"14","author":"Aedo-Lopez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvir.2024.06.006_bib50","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0924","article-title":"A\u00a0pilot feasibility study of yttrium-90 liver radioembolization followed by durvalumab and tremelimumab in patients with microsatellite stable colorectal cancer liver metastases","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jvir.2024.06.006_bib51","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1158\/1078-0432.CCR-23-0581","article-title":"A\u00a0phase I\/IIa trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jvir.2024.06.006_bib52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41417-019-0104-z","article-title":"HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases","volume":"27","author":"Katz","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jvir.2024.06.006_bib53","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2967\/jnumed.112.107482","article-title":"90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy","volume":"53","author":"Ezziddin","year":"2012","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jvir.2024.06.006_bib54","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/MNM.0000000000001284","article-title":"Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not?","volume":"41","author":"Yilmaz","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.jvir.2024.06.006_bib55","first-page":"S591","article-title":"Combined peptide radio-receptor therapy (PRRT) and liver selective internal radiation therapy (SIRT) in patients with metastatic neuroendocrine tumors: which is the best sequence?","volume":"45","author":"Follacchio","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jvir.2024.06.006_bib56","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3389\/fonc.2019.00624","article-title":"Regorafenib prior to selective internal radiation therapy using 90Y-resin microspheres for refractory metastatic colorectal cancer liver metastases: analysis of safety, dosimetry, and molecular markers","volume":"9","author":"Kennedy","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/JHC.S248314","article-title":"Survival outcomes for yttrium-90 transarterial radioembolization with and without sorafenib for unresectable hepatocellular carcinoma patients","volume":"7","author":"Teyateeti","year":"2020","journal-title":"J\u00a0Hepatocell Carcinoma"},{"key":"10.1016\/j.jvir.2024.06.006_bib58","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/cancers12040897","article-title":"Comparison between Y90 radioembolization plus sorafenib and Y90 radioembolization alone in the treatment of hepatocellular carcinoma: a propensity score analysis","volume":"12","author":"Facciorusso","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvir.2024.06.006_bib59","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.3747\/co.23.2827","article-title":"Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma","volume":"23","author":"Salman","year":"2016","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib60","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhep.2014.03.023","article-title":"Prospective randomized pilot study of Y90+\/-sorafenib as bridge to transplantation in hepatocellular carcinoma","volume":"61","author":"Kulik","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jvir.2024.06.006_bib61","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jvir.2020.11.011","article-title":"Safety and efficacy of arterially directed liver therapies in the treatment of hepatic metastatic ovarian cancer: a retrospective single-institution study","volume":"32","author":"Lacayo","year":"2021","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2024.06.006_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.754891","article-title":"Irinotecan-induced steatohepatitis: current insights","volume":"11","author":"Han","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib63","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2006.08.7916","article-title":"Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy","volume":"25","author":"Sharma","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib64","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","article-title":"Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203","volume":"24","author":"Gerard","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib65","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0959-8049(02)00076-X","article-title":"Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer","volume":"38","author":"de Lange","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jvir.2024.06.006_bib66","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1200\/JCO.1997.15.8.2910","article-title":"Phase II trial of irinotecan in patients with metastatic colorectal carcinoma","volume":"15","author":"Pitot","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib67","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvir.2024.06.006_bib68","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jvir.2024.06.006_bib69","first-page":"619","article-title":"Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications","volume":"23","author":"Milenic","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.jvir.2024.06.006_bib70","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1432-2277.2011.01299.x","article-title":"Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant","volume":"24","author":"Truesdale","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.jvir.2024.06.006_bib71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imm.13141","article-title":"Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms","volume":"159","author":"Fessas","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.jvir.2024.06.006_bib72","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111607","article-title":"Vascular normalization in immunotherapy: a promising mechanisms combined with radiotherapy","volume":"139","author":"Liu","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jvir.2024.06.006_bib74","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/RLU.0000000000000935","article-title":"Peptide receptor radionuclide therapy-induced hepatotoxicity in patients with metastatic neuroendocrine tumors","volume":"40","author":"Riff","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.jvir.2024.06.006_bib75","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MNM.0000000000001198","article-title":"Nephrotoxicity\/renal failure after therapy with 90yttrium- and 177lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review","volume":"41","author":"Stolniceanu","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.jvir.2024.06.006_bib76","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2008.20.8116","article-title":"Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy","volume":"27","author":"van Hazel","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib77","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clcc.2017.01.003","article-title":"Adherence, dosing, and managing toxicities with trifluridine\/tipiracil (TAS-102)","volume":"16","author":"Lee","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jvir.2024.06.006_bib78","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.21037\/jgo-21-96","article-title":"Narrative review of the role of yttrium-90 selective internal radiation therapy in the surgical management of colorectal liver metastases","volume":"12","author":"Moslim","year":"2021","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib79","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/bjs.11283","article-title":"Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial","volume":"106","author":"Garlipp","year":"2019","journal-title":"Br J Surg"},{"key":"10.1016\/j.jvir.2024.06.006_bib80","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.semnuclmed.2019.01.009","article-title":"Neoadjuvant radiation lobectomy as an alternative to portal vein embolization in hepatocellular carcinoma","volume":"49","author":"Gabr","year":"2019","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.jvir.2024.06.006_bib81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13550-022-00880-4","article-title":"Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy","volume":"12","author":"Ebbers","year":"2022","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.jvir.2024.06.006_bib82","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13139-014-0292-2","article-title":"Sequential use of (90)Y microspheres radioembolization and (177)Lu-Dotatate in pluri-metastatic neuroendocrine tumors: a case report","volume":"48","author":"Filippi","year":"2014","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.jvir.2024.06.006_bib83","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.critrevonc.2011.01.012","article-title":"Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)","volume":"80","author":"Goffredo","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jvir.2024.06.006_bib84","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1097\/RLU.0000000000002480","article-title":"Safety and efficacy of combined peptide receptor radionuclide therapy and liver selective internal radiation therapy in a patient with metastatic neuroendocrine tumor","volume":"44","author":"Maccauro","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.jvir.2024.06.006_bib85","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clbc.2020.02.010","article-title":"Combining adjuvant radiotherapy with capecitabine in chemotherapy-resistant breast cancer: feasibility, safety, and toxicity","volume":"20","author":"Sherry","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jvir.2024.06.006_bib86","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jvir.2024.06.006_bib87","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jvir.2024.06.006_bib89","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000355821","article-title":"Radioembolization with yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors","volume":"86","author":"Michl","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.jvir.2024.06.006_bib90","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1186\/s12885-015-1822-8","article-title":"Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma","volume":"15","author":"Gibbs","year":"2015","journal-title":"BMC Cancer"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044324003981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044324003981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T19:32:03Z","timestamp":1733772723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044324003981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":88,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1051044324003981"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2024.06.006","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the\u00a0Treatment of Liver Malignancy","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR 2024 .","name":"copyright","label":"Copyright"}]}}